Trial intelligence / Profile preview

iDose TR With iStent Infinite in Open-angle Glaucoma or Ocular Hypertension

NCT06066645Phase 4Recruiting

Sponsor
Glaukos Corporation
Start
Sep 2023
Primary completion
May 2027
Modality
Prodrugs/Conditional Activator Small Molecules
Countries
1
01

Overview

A Phase 4 trial of travoprost in open-angle glaucoma (OAG), ocular hypertension, sponsored by Glaukos Corporation. Started Sep 2023; status: recruiting.

02

Drugs

travoprost
03

Conditions

open-angle glaucoma (OAG)ocular hypertension

Beyond the preview

Go deeper on NCT06066645.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06066645.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call